Leronlimab has been proven completely safe with no drug interactions. Phase 2 and Phase 3 trials both showed positive results for Covid and HIV. What do we have to lose from an EUA? 

A recently approved IL-6 blocker used to treat severe to critical hospitalized COVID-19 patients requiring mechanical ventilation, reduced mortality by ONLY 2% compared to the placebo group. In contrast, leronlimab demonstrated a reduction of 24% in mortality compared to the SoC treated group, which is 12 TIMES BETTER in reducing all-cause mortality for critically ill COVID-19 patients